Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat + Azacitidine in Higher Risk MDS Patients With Azacitidine Failure
NCT01748240Phase 2Terminated
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Mar 2013
- Primary completion
- Oct 2013
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Started Mar 2013; status: terminated.
02
Drugs
vorinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01748240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01748240.